TITLE: Risk of preeclampsia in patients with genetic predisposition to common medical conditions: a case-control study

AUTHORS: Kathryn J. Gray, MD PhD^{1,4}, Vesela P. Kovacheva, MD PhD², Hooman Mirzakhani, MD PhD^{3,a}, Andrew C. Bjornes, MSc^{4,b}, Berta Almoguera, PhD⁵, Melissa L. Wilson, MPH PhD⁶, Sue Ann Ingles, DPH⁶, Charles J. Lockwood, MD⁷, Hakon Hakonarson, MD PhD^{5,8}, Thomas F. McElrath, MD PhD¹, Jeffrey C. Murray, MD⁹, Errol R. Norwitz, MD PhD MBA¹⁰, S. Ananth Karumanchi, MD^{11,12}, Brian T. Bateman, MD MSc^{3,c}, Brendan J. Keating, DPhil¹³, Richa Saxena, PhD^{3,4}

AFFILIATIONS:

¹ Division of Maternal-Fetal Medicine, Brigham and Women's Hospital, Boston, MA

² Department of Anesthesiology, Brigham and Women's Hospital, Boston, MAa

³ Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA

⁴ Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA

⁵ Center for Applied Genomics, Children's Hospital of Philadelphia, Philadelphia, PA

⁶ Department of Preventative Medicine, University of Southern California, Keck School of Medicine, Los Angeles, CA

⁷ University of South Florida, Morsani College of Medicine, Tampa, FL

⁸ Department of Pediatrics, Divisions of Human Genetics and Pulmonary Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

⁹ Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, IA

¹⁰ Department of Obstetrics & Gynecology, Tufts Medical Center, Boston, MA

¹¹ Center for Vascular Biology, Beth Israel Deaconess Medical Center, Boston, MA

¹² Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA

¹³ Department of Surgery and Pediatrics, University of Pennsylvania, Philadelphia, PA

PRESENT AFFILIATIONS:

^a Department of Medicine, Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA

^b Department of Biomedical Informatics, Harvard Medical School, Boston, MA

^c Department of Anesthesiology, Brigham and Women's Hospital, Boston, MA

CORRESPONDING AUTHOR:

Kathryn J. Gray, MD PhD

Division of Maternal-Fetal Medicine, Brigham and Women's Hospital

75 Francis St, CWN-3

Boston, MA, 02115, USA

Phone: 617-732-5452; Fax: 617-232-6346

Email: kgray6@bwh.harvard.edu

RUNNING TITLE: Preeclampsia genetic predisposition

Word count: 3500; **Abstract:** 246

ABSTRACT

Objective: To assess whether women with a genetic predisposition to medical conditions known to increase preeclampsia risk have an increased risk of preeclampsia in pregnancy.

Design: Case-control study.

Setting and population: Preeclampsia cases (n=498) and controls (n=1864) of European ancestry from 5 US sites genotyped on a cardiovascular gene-centric array.

Methods: Significant single nucleotide polymorphisms (SNPs) from 21 traits in 7 disease categories (cardiovascular, inflammatory/autoimmune, insulin resistance, liver, obesity, renal, thrombophilia) with published genome-wide association studies (GWAS) were used to create a genetic instrument for each trait. Multivariable logistic regression was used to test the association of each continuous, scaled genetic instrument with preeclampsia. Odds of preeclampsia were compared across quartiles of the genetic instrument and evaluated for significance using a test for trend.

Main Outcome Measures: preeclampsia.

Results: An increasing burden of risk alleles for elevated diastolic blood pressure (DBP) and increased body mass index (BMI) were associated with an increased risk of preeclampsia (DBP: overall OR 1.11 (1.01-1.21), $p=0.025$; BMI: OR 1.10 (1.00-1.20), $p=0.042$), while risk alleles associated with elevated alkaline phosphatase (ALP) were protective (OR 0.89 (0.82-0.97), $p=0.008$), driven primarily by pleiotropic effects of variants in the *FADS* gene region. The effect of DBP genetic loci was even greater in early-onset (<34 weeks) preeclampsia cases (OR 1.30 (1.08-1.56), $p=0.005$). For all other traits, the genetic instrument was not robustly associated with preeclampsia risk.

Conclusions: These results suggest that the underlying genetic architecture of preeclampsia is shared with other disorders, specifically hypertension and obesity.

KEYWORDS: cardiovascular risk; genetic epidemiology; genetic predisposition to disease; genetic risk score; preeclampsia; pregnancy

TWEETABLE ABSTRACT

Genetic predisposition to increased diastolic blood pressure and obesity increases the risk of preeclampsia.

INTRODUCTION

Preeclampsia (PE) is a severe, pregnancy-specific disorder affecting 3-8% of all gestations and characterized by new-onset hypertension and proteinuria after 20 weeks gestation. Despite extensive investigation, the etiology remains poorly understood and PE continues to be a leading cause of maternal and neonatal morbidity and mortality.

Genetics influence PE risk—multiple epidemiologic studies estimate the heritability at 55-60%, of which 30-35% is maternal and 20% fetal¹⁻⁴, with early-onset PE having the largest genetic component and environmental factors contributing more to late-onset PE⁵. Understanding PE heritability is challenging due to the involvement of two genomes (maternal and fetal), the heterogeneous nature of the disease, and limited availability of large, well-phenotyped PE cohorts⁶. Recently, the first fetal and maternal PE genome-wide association studies (GWAS) have been published revealing a few genetic loci contributing to risk⁷⁻¹¹; however, the majority of PE heritability remains unexplained.

Co-existing maternal medical conditions (e.g., diabetes, chronic hypertension, renal disease, autoimmune disease, antiphospholipid antibody syndrome) also increase PE risk^{12,13}. Many additional clinical risk factors for PE are well-established, including obesity, dyslipidemia, multifetal gestation, nulliparity, use of assisted reproductive technology, previous PE, and family history of PE or cardiovascular disease¹²⁻¹⁷. Specifically, women with chronic hypertension have a 16-25% risk of PE^{12,13}, and women with prior PE are more likely to use antihypertensive medications both the short- and long-term¹⁸. For obesity, the higher the BMI, the greater the risk of PE; women who are obese (BMI >35) have a 3-fold increased risk¹⁹⁻²³. For dyslipidemia, PE is

associated with elevated total cholesterol, non-HDL cholesterol, and triglycerides throughout pregnancy, as well as with lower HDL levels in the third trimester^{16,24,25}. Additionally, following a pregnancy with PE, women have a 2-4-fold increased lifetime risk of cardiovascular disease (CVD)^{26–29}.

Given this, we hypothesized that women with genetic predisposition to these medical conditions would have an increased risk of PE. To test this hypothesis, we identified single nucleotide polymorphisms (SNPs) for relevant traits from the largest published European genome-wide association studies (GWAS) for each trait and tested whether these SNPs increased PE risk in a maternal case/control sample of European ancestry from the United States genotyped using the ITMAT-Broad-CARe (IBC) genotyping array, that captures genetic diversity across >2000 candidate gene regions related to cardiovascular, inflammatory, and metabolic phenotypes³⁰.

METHODS

Study population

We utilized maternal GWAS data from a previously assembled IRB-approved cohort⁸ with European-ancestry cases (n=498) and controls (n=449) from five US cities and population controls from the National Heart, Lung, and Blood Institute (NHLBI) studies, Atherosclerosis Risk in Communities (ARIC; n=645)³¹ and Coronary Artery Risk Development in Young Adults (CARDIA; n=770)³², for a total of 498 cases and 1864 controls (Table 1). The published GWAS describes the specifics of the maternal sample collection, genotyping, and quality control for this cohort⁸. PE status at all sites was defined by standard American Congress of Obstetrician and

Gynecologists (ACOG) criteria³³. Controls from the US sites were normotensive pregnant women without medical co-morbidities.

Identification of traits and their associated single nucleotide polymorphisms (SNPs)

The GWAS Catalog, curated by the National Human Genome Research Institute (NHGRI) and the European Bioinformatics Institute (EBI), was used to identify genome-wide association studies performed up to the year 2017 in individuals of European ancestry for traits known to be associated with PE³⁴. We searched specifically for studies on traits in 7 categories: cardiovascular, inflammatory/ autoimmune, insulin resistance, liver, obesity, renal, and thrombophilia (Table 2).

Within the cardiovascular category, we identified GWAS for systolic and diastolic blood pressure³⁵, total cholesterol^{36,37}, low-density lipoprotein (LDL)^{36,37}, high-density lipoprotein (HDL)^{36,37}, triglycerides^{36,37}, coronary artery disease (CAD)^{38,39}, and ischemic stroke⁴⁰. PE is highly associated with hypertension both prior to and following pregnancy^{12,13}. Other cardiovascular risk factors including increased levels of total cholesterol, LDL-C, and triglycerides and decreased levels of HDL-C have also been associated with PE^{24,41}. The increased long-term risk of cardiovascular disease in women with prior PE includes an increased risk of CAD, ischemic stroke, heart failure, cardiac procedures, and cardiovascular-related hospitalizations^{26–29,42,43}.

Within the inflammatory/autoimmune category, we identified GWAS for C-reactive protein (CRP)⁴⁴ and systemic lupus erythematosus (SLE)⁴⁵. Women with increased CRP are at significantly increased risk of PE, even after adjustment for clinical confounders such as BMI⁴⁶. Women with SLE are at increased risk of PE, particularly early-onset PE, even after adjustment

for chronic hypertension and antiphospholipid antibody syndrome (APS)⁴⁷. While lupus nephritis, APS, and chronic hypertension with SLE are associated with the highest risk of PE, even uncomplicated SLE in remission is associated with increased risk⁴⁸.

Within the insulin resistance category, we identified GWAS for adiponectin⁴⁹, fasting glucose⁴⁹, fasting insulin⁵⁰, type 2 diabetes mellitus (T2DM)⁵¹, and polycystic ovarian syndrome (PCOS)⁵². Women with pregestational or gestational diabetes have a 2-4 fold increased PE risk and non-diabetic women with PE are at increased risk of later T2DM⁵³. Adiponectin levels are associated with the development of gestational diabetes^{54,55}. Women with PCOS have a high rate of metabolic syndrome and significantly higher risks of adverse pregnancy outcomes including PE⁵⁶.

Within the liver category, we identified GWAS for alkaline phosphatase (ALP)⁵⁷, gamma-glutamyl transferase (GTT)⁵⁷, and alanine aminotransferase (ALT)⁵⁷. Women with liver dysfunction during pregnancy (e.g., intrahepatic cholestasis of pregnancy) are at increased risk for PE⁵⁸. Also, transaminitis is a key diagnostic feature for particular PE subtypes, including PE with severe features and HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome³³.

Within the thrombophilia category, we identified GWAS for fibrinogen⁵⁹ and venous thromboembolism (VTE)⁶⁰. PE is associated with a state of hypercoagulability. Specifically, fibrinogen levels are elevated in women with PE⁶¹ and women with PE are at significantly increased risk of VTE^{42,62}. Although antiphospholipid antibody syndrome is a strong clinical risk factor for PE, the only published GWAS is a small study of Japanese women⁶³.

Within the obesity category, we identified GWAS for body mass index (BMI)⁶⁴ and maternal birthweight⁶⁵. Increased BMI is a prevalent risk factor for PE and the degree of obesity is directly correlated to the level of risk^{19–23}. We included maternal birthweight as women who are small at birth and obese as adults have a particularly high risk of PE⁶⁶.

Within the renal category, we identified GWAS for estimated glomerular filtration rate from serum creatinine (eGFR_{Cr})⁶⁷ and uric acid⁶⁸. Women with decreased GFR prior to pregnancy are at increased risk of PE^{69,70}, and women with PE have a reduced GFR^{71,72}. In addition to its role as a marker for renal function, elevations in uric acid are associated with PE and may contribute directly to disease pathogenesis^{73–75}.

For each of the above traits, the most recent and largest published GWAS (up to the year 2017) for individuals of European ancestry was identified and trait-associated SNPs with p -values $\leq 1.0 \times 10^{-6}$ were curated (see Supplementary Tables S1-S21 for each trait). For each curated SNP, we determined if the SNP was genotyped on the IBC array used in our cohort³⁰. If the SNP was not present on the array, we determined if a proxy SNP was present in the 1000 Genomes phase 3 (1KGPv3) CEU population⁷⁶ using SNAP, the SNP Annotation and Proxy Search available through the Broad Institute⁷⁷. For each proxy, the proxy SNP with the strongest correlation was chosen. Most proxy SNPs had $r^2 > 0.8$, and only SNPs with proxies of $r^2 > 0.5$ were included in our analyses (see Supplementary Tables S1-S21). Using this approach, the noted number of SNPs were available for each trait (Table 3).

After curation of these GWAS and their associated SNPs, we had a total of 21 distinct traits within 7 categories with SNPs or proxy SNPs available (Table 2). Some traits of interest (alanine aminotransferase (ALT), fasting insulin, polycystic ovarian syndrome (PCOS)) could not be included in analysis as the implicated SNPs were not genotyped in our cohort. Of note, while newer GWAS have been published since 2017 for some of the selected traits, the additional loci reported could not be examined as our cohort was genotyped on the gene-centric IBC array (which has limited SNPs compared to newer arrays) and the additional loci or proxies were not available in our data.

Statistical Analysis

Determination of genetic instruments

For each trait, we derived a genetic instrument to assess risk for each individual participant by summing the number of risk SNPs, which were weighted by the respective allelic effect size (β -coefficient) from the original discovery cohort using PLINK, as previously described^{78–81}. If genotype data were missing for a particular individual for a particular SNP, then the expected value was imputed based on the sample allele frequency of the SNP (in total, this affected very few loci (<5%), as SNPs were removed for call rates <95%). Scaling of the genetic instrument for each trait was performed to allow interpretation of the effects on PE as a per-1 risk allele increase in the total sum of risk SNPs for each trait (division by twice the sum of the β -coefficients and multiplication by twice the SNP count representing the maximum number of risk alleles). Multivariable logistic regression in R was used to test the association of each continuous, scaled genetic instrument with PE, adjusted for study site and principal components of ancestry, leading to an adjusted, overall

odds ratio. The odds of PE were compared across quartiles of each genetic instrument and evaluated for significance using a test for trend.

RESULTS

The distribution of European ancestry PE cases and normotensive controls between the 5 US sites, as well as the population controls, is shown in Table 1. As noted previously, the cases in this sample are enriched for early-onset PE (diagnosis <37 weeks gestation; 40%), hemolysis-elevated liver enzymes-low platelets (HELLP) syndrome (29%), and PE with severe features (43%)⁸.

For each of the 21 traits identified, the derived genetic instrument was used to assess the risk of PE conferred by the trait-associated risk SNPs (Table 3). For the cardiovascular traits, we found that an increasing burden of risk alleles for elevated diastolic blood pressure (DBP) was associated with increased PE risk at all quartiles of risk with an overall OR of 1.11 (1.01-1.21), $p=0.025$, per risk allele. For coronary artery disease (CAD), patients in the third quartile of risk had a significantly increased risk of PE compared to the reference group (OR 1.43 (1.08-1.90), $p=0.014$), while for HDL, patients in the third quartile had a significantly decreased risk of PE compared to the reference (OR 0.70 (0.53-0.93), $p = 0.014$). In this analysis, we did not find an association of the genetic instruments for systolic blood pressure (SBP), total cholesterol, LDL, triglycerides, or ischemic stroke with PE. For the inflammatory/ autoimmune traits, we did not find an association between CRP or SLE-associated genetic instruments and PE. Similarly, for the insulin resistance traits, adiponectin, fasting glucose, and type 2 diabetes (T2DM), the genetic instruments were not significantly associated with PE.

For the liver traits, gamma-glutamyl transferase (GTT)-associated risk alleles were not significantly associated with PE. However, an increasing burden of risk alleles for elevated alkaline phosphatase (ALP) levels was surprisingly protective for PE (overall OR 0.89 (0.82-0.97),

p=0.008). As this result was not anticipated, we examined the particular SNPs (n=5) used to create the ALP genetic instrument in further detail (Supplementary Table S2; SNPs from most comprehensive GWAS of plasma liver enzyme concentrations⁵⁷). Of these 5 SNPs, 2 SNPs contributed most significantly to the protective nature of the ALP variants: rs174601 (associated with *FADS1*, *FADS2*, and *C11orf10* gene expression) and rs579459 (near the *ABO* gene) (data not shown).

For the obesity traits, an increasing burden of risk alleles for increased body mass index (BMI) was associated with increased PE risk (overall OR 1.10 (1.00-1.20), p=0.042). The genetic instrument for maternal birthweight, however, was not associated with PE risk. For the renal traits, patients in the second quartile of risk for increased GFR, had a decreased risk of PE (OR 0.75 (0.57-0.99), p=0.044). In contrast, the genetic instrument for uric acid was not significantly associated with PE. For the thrombophilia traits, patients in the second quartile of genetic risk for VTE had a decreased risk of PE (OR 0.66 (0.49-0.89), p=0.006), while the genetic instrument for fibrinogen was not significantly associated with PE.

As early-onset PE has the strongest genetic predisposition⁵, we performed a sensitivity analysis for all 21 traits on the subset of PE cases with delivery < 34 weeks (n=103 cases) and < 37 weeks (n=201 cases). In the subset of cases with early-onset PE, the effect of DBP-associated risk alleles was greater than in the overall cohort (<34 weeks: overall OR 1.30 (1.08-1.56), p=0.005; <37 weeks: overall OR 1.19 (1.05-1.36), p=0.009) (Table 4). In contrast, the effects of BMI and ALP-associated risk alleles were diminished (BMI, <34 weeks: overall OR 1.04 (0.87-1.24), p=0.683; <37 weeks: overall OR 1.06 (0.93-1.21), p=0.400. ALP, <34 weeks: overall OR 0.86 (0.72-1.03),

$p=0.108$; <37 weeks: overall OR 0.82 (0.72-0.94), $p=0.004$) (Table 4). For all other traits examined, the effects of the genetic instruments were not significant in the early-onset subgroup (data not shown).

DISCUSSION

Main Findings

Here we detail the first comprehensive analysis of the effect of genetic predisposition for 21 clinical traits on PE risk, utilizing data from the largest published US maternal PE GWAS⁸. Among the 21 traits examined, risk alleles for elevated DBP and increased BMI were most robustly associated with PE risk, while risk alleles associated with elevated ALP levels were protective. Additionally, we identified a suggestive risk effect for coronary artery disease and possible protective effects for increased HDL, GFR, and VTE risk. The effect of DBP-associated risk alleles was strongest in early-onset PE cases, while the effects of BMI and ALP-associated risk alleles were diminished in this subset, suggesting that these effects are more important in late-onset disease. For the other traits examined, we did not find significant associations.

Strengths and Limitations

Strengths of this study include utilization of the largest US-based maternal PE cohort with genome-wide SNP data reported to date and a comprehensive examination of PE-associated traits. This cohort is enriched with early-onset and severe cases that are more likely to have a genetic predisposition to PE⁵.

Despite its size relative to many other PE genetic studies, this cohort has a limited sample size for assessment of common genetic variation associated with disease. Additionally, the genotyping was performed several years ago on a platform with limited SNPs (a gene-centric array with 50K SNPs) compared to those now readily available. These limitations mean that PE may share overlapping genetic features with additional traits, but to detect these effects, larger

cohorts with higher-coverage genotyping or sequencing will be required. In general, for each trait examined, the power to detect a significant association is dependent on the degree of heritability of the trait, the amount of heritability explained by risk alleles in the literature, and the number of risk alleles assessed on the genotyping array. For example, for hypertension, we demonstrated overlapping genetic architecture between DBP and PE, but not SBP. However, the heritability of SBP and DBP is estimated at ~20% and 50%, respectively, in European ancestry individuals⁸²; thus, we would expect shared genetic architecture of DBP and PE to be demonstrated in a smaller cohort than that required to demonstrate shared genetics of SBP and PE. For specific traits potentially associated with PE (e.g. PCOS, fasting insulin), an assessment could not be performed as there were no proxies on our array for the literature SNPs.

Interpretation

Prior studies have examined whether genetic predisposition to specific cardiovascular-associated traits (i.e., maternal essential hypertension⁸³, dyslipidemia⁸⁴, and CRP⁸⁵) predisposes women to PE. For essential hypertension genetics and PE risk, a similar approach was used and no significant association was found⁸³. However, this analysis was done in a smaller cohort (162 PE cases, 108 controls) using risk alleles from a 2011 hypertension GWAS⁸⁶. The genetic instrument included 6 SBP and 6 DBP risk alleles⁸³. In our analysis, an expanded set of risk alleles for SBP (19 SNPs) and DBP (16 SNPs) were used from a subsequent GWAS³⁵ in a larger cohort. Thus, we had increased power to detect an association. For dyslipidemia, lower HDL was marginally associated with increased PE risk^{84,85}, similar to our observation that risk alleles associated with increased HDL had a suggestive association with decreased PE risk. For the study of CRP (which again used a smaller cohort and fewer SNPs), increased genetic risk for elevated CRP was associated with

decreased PE risk^{84,85}, which is in contrast to the clinical association of increased CRP with increased PE risk⁴⁶. These findings warrant further interrogation in larger cohorts.

The specific mechanisms by which known clinical risk factors—including hypertension, obesity, and diabetes—contribute to PE development, as well as long-term CVD risk, have not been fully elucidated. Our results suggest that genetic risk factors shared between particular traits (i.e., hypertension, obesity, CAD) and PE may be involved both in the pathogenesis of PE itself and in later CVD development. In published hypertension GWAS, risk loci are enriched for regulatory elements affecting gene expression in vascular endothelial cells and are associated with end organ damage in the heart, cerebral vessels, carotid artery, and the eye³⁵. As PE is characterized by diffuse endothelial dysfunction⁸⁷, women with genetic predisposition to altered vascular endothelial cell function are likely to be at high risk for PE. This idea is directly supported by the results of the maternal PE GWAS performed on this same cohort⁸ where the variant, rs9478812 near the gene, *PLEKHG1*, was identified; this locus has been associated with blood pressure in an independent GWAS⁸⁸. In published CAD GWAS, risk loci are highly associated with lipid traits and blood pressure, and pathway analyses highlight lipid metabolism and inflammation as key underlying biological processes⁸⁹, processes also highly associated with PE^{24,90–92}. In published obesity GWAS, identified risk loci are highly associated with brain regions important for appetite regulation, learning, emotion, and memory⁶⁴, as well as insulin utilization, energy/lipid metabolism, and adipogenesis in other tissues⁶⁴. Whether these pathways directly contribute to underlying PE pathophysiology or are mediated through BMI-related effects, is an important question for future investigations.

At first glance, the ALP and VTE effects related to PE were surprising, as they were in the opposite directions as anticipated. However, further investigation provides some useful insight. For ALP, increased levels are commonly associated with biliary obstruction, but ALP is also present in bone, intestine, leukocytes, and placenta⁹³. Of the 5 SNPs used in the ALP genetic instrument, 2 SNPs drove the association—rs174601 and rs579459. The SNP, rs174601, is associated with decreased *FADS1* and *FADS2* expression in the liver and decreased *FADS1* and increased *FADS2* and *C11orf10* expression in peripheral leukocytes⁵⁷. *FADS1* and *FADS2* are associated with circulating fatty acids in plasma, as well as CAD and ischemic stroke risk⁹⁴. The function of *C11orf10* remains unknown. The SNP, rs579459, is an upstream variant near the *ABO* gene, which encodes for ABO blood group system proteins. C-allele carriers of the rs579459 SNP (corresponding to blood group A) have increased LDL cholesterol⁹⁵ and an increased risk of adverse cardiac outcomes⁹⁶. Thus, the apparent protective nature of SNPs associated with elevated ALP for PE may instead reflect the pleiotropic nature of these SNPs, particularly in relationship to cardiovascular traits.

For VTE, while it is clinically-recognized that women with PE are at significantly increased risk of VTE^{42,62}, thrombosis is also a trait highly-associated with recurrent pregnancy loss^{97,98}. Given this, women with the highest genetic risk for VTE may have a reduced rate of live births, leading to a decreased expression of all pregnancy-related phenotypes including PE. We hypothesize that this relationship may explain the lower rate of PE seen in women with increased genetic risk for VTE.

Distinct molecular subtypes of PE that go beyond the distinction of early vs. late-onset disease are emerging^{99–101}. While much work remains to define these subtypes, our analysis suggests

clustering of different trait associations within the broad categories of early vs. late-onset. Specifically, patients with increased genetic risk for elevated DBP are more likely to develop early-onset PE, while patients with increased genetic risk for obesity are more likely to develop term PE. As larger cohorts with more detailed PE phenotyping and genetics emerge, molecular subtyping of PE can be refined further based on both maternal and fetal genetic risk.

CONCLUSIONS

In conclusion, using curated literature genetic risk loci, we provide the first comprehensive analysis of the overlap of maternal PE genetic architecture with the genetic architecture of other disorders, revealing an overlap of hypertension and obesity genetics with PE. These results implicate underlying genetics as a causal factor for both the pathogenesis of PE itself and the development of later CVD. Expanding understanding of PE heritability will require the establishment of larger maternal and fetal PE consortia with detailed phenotyping and genome-wide genotyping/sequencing. Future analyses should focus not only on the independent effects of the maternal and fetal genomes on disease pathogenesis, but also how the interplay of the two genomes contributes to disease. Such endeavors will allow for more comprehensive delineation of PE heritability and the overlap of PE genetics with the genetic underpinnings of other common diseases.

Disclosure of Interests: BTB is an investigator on grants to his institution from Lilly, Pfizer, Pacira, Baxalta, and GSK and is a consultant to Aetion, Inc for unrelated projects. KJG has consulted for Quest Diagnostics, Illumina, and BillionToOne for unrelated projects. All other authors report no conflicts of interest.

Contribution to Authorship:

All authors contributed to the conception, design, participant recruitment and data collection in the present study. ACB, KJG, and RS were involved in data analysis. KJG and RS drafted the manuscript. All authors were involved in interpreting the data and critically reviewing the manuscript. All authors gave approval of the final version of the manuscript.

Details of Ethics Approval:

The study was approved under Partners IRB protocol #2011P001053 and #2014P000719, as well as the ethics committees at all participating institutions.

Funding: This work was supported by a Society for Obstetric Anesthesia and Perinatology Gertie Marx Research grant (to RS and BTB), funds from the Howard Hughes Medical Institute (to SAK), NIH K08 HD075831 grant (to BTB), NIH F32 HD86948, NIH K12 HD051959 BIRCWH, and NIH K08 HL146963 grants (to KJG), NIH T32 HL007427 and NHLBI L30 HL129467 grants (to HM), NIH R21 HD046624 (to SAI) and March of Dimes grants #21-FY05-1250 (to ERN) and #20-FY03-30 (to CJL).

REFERENCES

1. Cnattingius S, Reilly M, Pawitan Y, Lichtenstein P. Maternal and fetal genetic factors account for most of familial aggregation of preeclampsia: a population-based Swedish cohort study. *Am J Med Genet A*. 2004 Nov 1;130A(4):365–71.
2. Esplin MS, Fausett MB, Fraser A, Kerber R, Mineau G, Carrillo J, et al. Paternal and maternal components of the predisposition to preeclampsia. *N Engl J Med*. 2001 Mar 22;344(12):867–72.
3. Nilsson E, Salonen Ros H, Cnattingius S, Lichtenstein P. The importance of genetic and environmental effects for pre-eclampsia and gestational hypertension: a family study. *BJOG*. 2004 Mar;111(3):200–6.
4. Thomsen LCV, Melton PE, Tollaksen K, Lyslo I, Roten LT, Odland ML, et al. Refined phenotyping identifies links between preeclampsia and related diseases in a Norwegian preeclampsia family cohort. *J Hypertens*. 2015 Nov;33(11):2294–302.
5. Boyd HA, Tahir H, Wohlfahrt J, Melbye M. Associations of personal and family preeclampsia history with the risk of early-, intermediate- and late-onset preeclampsia. *Am J Epidemiol*. 2013 Dec 1;178(11):1611–9.
6. Laivuori H. Pitfalls in setting up genetic studies on preeclampsia. *Pregnancy Hypertens*. 2013 Apr;3(2):60.
7. McGinnis R, Steinthorsdottir V, Williams NO, Thorleifsson G, Shooter S, Hjartardottir S, et al. Variants in the fetal genome near FLT1 are associated with risk of preeclampsia. *Nat Genet*. 2017;49(8):1255-1260.
8. Gray KJ, Kovacheva VP, Mirzakhani H, Bjornes AC, Almoguera B, DeWan AT, et al. Gene-Centric Analysis of Preeclampsia Identifies Maternal Association at PLEKHG1. *Hypertension*. 2018 Aug;72(2):408–16.
9. Zhao L, Bracken MB, DeWan AT. Genome-wide association study of pre-eclampsia detects novel maternal single nucleotide polymorphisms and copy-number variants in subsets of the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study cohort. *Ann Hum Genet*. 2013 Jul;77(4):277–87.
10. Zhao L, Triche EW, Walsh KM, Bracken MB, Saftlas AF, Hoh J, et al. Genome-wide association study identifies a maternal copy-number deletion in PSG11 enriched among preeclampsia patients. *BMC Pregnancy Childbirth*. 2012 Jun 29;12:61.
11. Johnson MP, Brennecke SP, East CE, Göring HHH, Kent JW Jr, Dyer TD, et al. Genome-wide association scan identifies a risk locus for preeclampsia on 2q14, near the inhibin, beta B gene. *PLoS One*. 2012 Mar 14;7(3):e33666.
12. Bartsch E, Medcalf KE, Park AL, Ray JG, High Risk of Pre-eclampsia Identification Group.

Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. *BMJ*. 2016 Apr 19;353:i1753.

13. Caritis S, Sibai B, Hauth J, Lindheimer M, VanDorsten P, Klebanoff M, et al. Predictors of pre-eclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. *Am J Obstet Gynecol*. 1998 Oct;179(4):946–51.
14. LeFevre ML, U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med*. 2014 Dec 2;161(11):819–26.
15. Ness RB, Markovic N, Bass D, Harger G, Roberts JM. Family history of hypertension, heart disease, and stroke among women who develop hypertension in pregnancy. *Obstet Gynecol*. 2003 Dec;102(6):1366–71.
16. Barrett HL, Dekker Nitert M, McIntyre HD, Callaway LK. Maternal lipids in pre-eclampsia: innocent bystander or culprit? *Hypertens Pregnancy*. 2014 Nov;33(4):508–23.
17. Paré E, Parry S, McElrath TF, Pucci D, Newton A, Lim K-H. Clinical risk factors for preeclampsia in the 21st century. *Obstet Gynecol*. 2014 Oct;124(4):763–70.
18. Engeland A, Bjørge T, Klungsøyr K, Skjærven R, Skurtveit S, Furu K. Preeclampsia in pregnancy and later use of antihypertensive drugs. *Eur J Epidemiol*. 2015 Jun;30(6):501–8.
19. Thornburg LL. Antepartum obstetrical complications associated with obesity. *Semin Perinatol*. 2011 Dec;35(6):317–23.
20. Sibai BM, Ewell M, Levine RJ, Klebanoff MA, Esterlitz J, Catalano PM, et al. Risk factors associated with preeclampsia in healthy nulliparous women. The Calcium for Preeclampsia Prevention (CPEP) Study Group. *Am J Obstet Gynecol*. 1997 Nov;177(5):1003–10.
21. Mission JF, Marshall NE, Caughey AB. Pregnancy risks associated with obesity. *Obstet Gynecol Clin North Am*. 2015 Jun;42(2):335–53.
22. Athukorala C, Rumbold AR, Willson KJ, Crowther CA. The risk of adverse pregnancy outcomes in women who are overweight or obese. *BMC Pregnancy Childbirth*. 2010 Sep 17;10:56.
23. Lim CC, Mahmood T. Obesity in pregnancy. *Best Pract Res Clin Obstet Gynaecol*. 2015 Apr;29(3):309–19.
24. Spracklen CN, Smith CJ, Saftlas AF, Robinson JG, Ryckman KK. Maternal hyperlipidemia and the risk of preeclampsia: a meta-analysis. *Am J Epidemiol*. 2014 Aug 15;180(4):346–58.
25. Gallos ID, Sivakumar K, Kilby MD, Coomarasamy A, Thangaratinam S, Vatish M. Pre-eclampsia is associated with, and preceded by, hypertriglyceridaemia: a meta-analysis.

BJOG. 2013 Oct;120(11):1321–32.

26. Newstead J, von Dadelszen P, Magee LA. Preeclampsia and future cardiovascular risk. *Expert Rev Cardiovasc Ther.* 2007 Mar;5(2):283–94.
27. Chen CW, Jaffe IZ, Karumanchi SA. Pre-eclampsia and cardiovascular disease. *Cardiovasc Res.* 2014 Mar 15;101(4):579–86.
28. Ahmed R, Dunford J, Mehran R, Robson S, Kunadian V. Pre-eclampsia and future cardiovascular risk among women: a review. *J Am Coll Cardiol.* 2014 May 13;63(18):1815–22.
29. White WM, Mielke MM, Araoz PA, Lahr BD, Bailey KR, Jayachandran M, et al. A history of preeclampsia is associated with a risk for coronary artery calcification 3 decades later. *Am J Obstet Gynecol.* 2016 Apr;214(4):519.e1–8.
30. Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS, Glessner JT, et al. Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. *PLoS One.* 2008 Oct 31;3(10):e3583.
31. The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. *Am J Epidemiol.* 1989 Apr;129(4):687–702.
32. Friedman GD, Cutter GR, Donahue RP, Hughes GH, Hulley SB, Jacobs DR Jr, et al. CARDIA: study design, recruitment, and some characteristics of the examined subjects. *J Clin Epidemiol.* 1988;41(11):1105–16.
33. American College of Obstetricians and Gynecologists, Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. *Obstet Gynecol.* 2013 Nov;122(5):1122–31.
34. Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H, et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. *Nucleic Acids Res.* 2014 Jan;42(Database issue):D1001–6.
35. Ehret GB, Ferreira T, Chasman DI, Jackson AU, Schmidt EM, Johnson T, et al. The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals. *Nat Genet.* 2016 Oct;48(10):1171–1184.
36. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, et al. Discovery and refinement of loci associated with lipid levels. *Nat Genet.* 2013 Nov;45(11):1274–83.
37. Surakka I, Horikoshi M, Mägi R, Sarin A-P, Mahajan A, Lagou V, et al. The impact of low-frequency and rare variants on lipid levels. *Nat Genet.* 2015 Jun;47(6):589–97.
38. Nikpay M, Goel A, Won H-H, Hall LM, Willenborg C, Kanoni S, et al. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease.

- Nat Genet. 2015 Oct;47(10):1121–30.
39. Verweij N, Eppinga RN, Hagemmeijer Y, van der Harst P. Identification of 15 novel risk loci for coronary artery disease and genetic risk of recurrent events, atrial fibrillation and heart failure. *Sci Rep*. 2017 Jun 5;7(1):2761.
 40. Neurology Working Group of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, the Stroke Genetics Network (SiGN), and the International Stroke Genetics Consortium (ISGC). Identification of additional risk loci for stroke and small vessel disease: a meta-analysis of genome-wide association studies. *Lancet Neurol*. 2016 Jun;15(7):695–707.
 41. Ephraim R, Doe P, Amoah S, Antoh E. Lipid Profile and High Maternal Body Mass Index is Associated with Preeclampsia: A Case-Control Study of the Cape Coast Metropolis. *Ann Med Health Sci Res*. 2014 Sep;4(5):746–50.
 42. Bellamy L, Casas J-P, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and cancer in later life: systematic review and meta-analysis. *BMJ*. 2007 Nov 10;335(7627):974.
 43. Leon LJ, McCarthy FP, Direk K, Gonzalez-Izquierdo A, Prieto-Merino D, Casas JP, et al. Preeclampsia and Cardiovascular Disease in a Large UK Pregnancy Cohort of Linked Electronic Health Records: A CALIBER Study. *Circulation*. 2019 Sep 24;140(13):1050–60.
 44. Dehghan A, Dupuis J, Barbalic M, Bis JC, Eiriksdottir G, Lu C, et al. Meta-analysis of genome-wide association studies in >80 000 subjects identifies multiple loci for C-reactive protein levels. *Circulation*. 2011 Feb 22;123(7):731–8.
 45. Bentham J, Morris DL, Cunninghame Graham DS, Pinder CL, Tombleson P, Behrens TW, et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus. *Nat Genet*. 2015 Dec;47(12):1457–64.
 46. Qiu C, Luthy DA, Zhang C, Walsh SW, Leisenring WM, Williams MA. A prospective study of maternal serum C-reactive protein concentrations and risk of preeclampsia. *Am J Hypertens*. 2004 Feb;17(2):154–60.
 47. Simard JF, Arkema EV, Nguyen C, Svenungsson E, Wikström A-K, Palmsten K, et al. Early-onset Preeclampsia in Lupus Pregnancy. *Paediatr Perinat Epidemiol*. 2017 Jan;31(1):29–36.
 48. Phansene S, Sekararithi R, Jatavan P, Tongsong T. Pregnancy outcomes among women with systemic lupus erythematosus: a retrospective cohort study from Thailand. *Lupus*. 2018 Jan;27(1):158–64.
 49. Tyrrell J, Richmond RC, Palmer TM, Feenstra B, Rangarajan J, Metrustry S, et al. Genetic Evidence for Causal Relationships Between Maternal Obesity-Related Traits and Birth Weight. *JAMA*. 2016 Mar 15;315(11):1129–40.

50. Manning AK, Hivert M-F, Scott RA, Grimsby JL, Bouatia-Naji N, Chen H, et al. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. *Nat Genet.* 2012 May 13;44(6):659–69.
51. Scott RA, Scott LJ, Mägi R, Marullo L, Gaulton KJ, Kaakinen M, et al. An Expanded Genome-Wide Association Study of Type 2 Diabetes in Europeans. *Diabetes.* 2017 Nov;66(11):2888–902.
52. Hayes MG, Urbanek M, Ehrmann DA, Armstrong LL, Lee JY, Sisk R, et al. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. *Nat Commun.* 2015 Aug 18;6:7502.
53. Weissgerber TL, Mudd LM. Preeclampsia and diabetes. *Curr Diab Rep.* 2015 Mar;15(3):9.
54. Atègbo J-M, Grissa O, Yessoufou A, Hichami A, Dramane KL, Moutairou K, et al. Modulation of adipokines and cytokines in gestational diabetes and macrosomia. *J Clin Endocrinol Metab.* 2006 Oct;91(10):4137–43.
55. Bao W, Baecker A, Song Y, Kiely M, Liu S, Zhang C. Adipokine levels during the first or early second trimester of pregnancy and subsequent risk of gestational diabetes mellitus: A systematic review. *Metabolism.* 2015 Jun;64(6):756–64.
56. Boomsma CM, Eijkemans MJC, Hughes EG, Visser GHA, Fauser BCJM, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. *Hum Reprod Update.* 2006 Nov;12(6):673–83.
57. Chambers JC, Zhang W, Sehmi J, Li X, Wass MN, Van der Harst P, et al. Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. *Nat Genet.* 2011 Nov;43(11):1131–8.
58. Raz Y, Lavie A, Vered Y, Goldiner I, Skornick-Rapaport A, Landsberg Asher Y, et al. Severe intrahepatic cholestasis of pregnancy is a risk factor for preeclampsia in singleton and twin pregnancies. *Am J Obstet Gynecol.* 2015 Sep;213(3):395.e1–8.
59. de Vries PS, Chasman DI, Sabater-Lleal M, Chen M-H, Huffman JE, Steri M, et al. A meta-analysis of 120 246 individuals identifies 18 new loci for fibrinogen concentration. *Hum Mol Genet.* 2016 Jan 15;25(2):358–70.
60. Germain M, Chasman DI, de Haan H, Tang W, Lindström S, Weng L-C, et al. Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism. *Am J Hum Genet.* 2015 Apr 2;96(4):532–42.
61. Manten GTR, Sikkema JM, Franx A, Hameeteman TM, Visser GHA, de Groot PG, et al. Increased high molecular weight fibrinogen in pre-eclampsia. *Thromb Res.* 2003;111(3):143–7.
62. Egan K, Kevane B, Ní Áinle F. Elevated venous thromboembolism risk in preeclampsia:

- molecular mechanisms and clinical impact. *Biochem Soc Trans.* 2015 Aug;43(4):696–701.
63. Sugiura-Ogasawara M, Omae Y, Kawashima M, Toyo-Oka L, Khor S-S, Sawai H, et al. The first genome-wide association study identifying new susceptibility loci for obstetric antiphospholipid syndrome. *J Hum Genet.* 2017 Sep;62(9):831–8.
 64. Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body mass index yield new insights for obesity biology. *Nature.* 2015 Feb 12;518(7538):197–206.
 65. Horikoshi M, Beaumont RN, Day FR, Warrington NM, Kooijman MN, Fernandez-Tajes J, et al. Genome-wide associations for birth weight and correlations with adult disease. *Nature.* 2016 Sep 28;538(7624):248–52.
 66. Dempsey JC, Williams MA, Luthy DA, Emanuel I, Shy K. Weight at birth and subsequent risk of preeclampsia as an adult. *Am J Obstet Gynecol.* 2003 Aug;189(2):494–500.
 67. Pattaro C, Teumer A, Gorski M, Chu AY, Li M, Mijatovic V, et al. Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. *Nat Commun.* 2016 Jan 21;7:10023.
 68. Köttgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. *Nat Genet.* 2013 Feb;45(2):145–54.
 69. Bramham K, Briley AL, Seed PT, Poston L, Shennan AH, Chappell LC. Pregnancy outcome in women with chronic kidney disease: a prospective cohort study. *Reprod Sci.* 2011 Jul;18(7):623–30.
 70. Piccoli GB, Cabiddu G, Attini R, Vigotti FN, Maxia S, Lepori N, et al. Risk of Adverse Pregnancy Outcomes in Women with CKD. *J Am Soc Nephrol.* 2015 Aug;26(8):2011–22.
 71. Jeyabalan A, Conrad KP. Renal function during normal pregnancy and preeclampsia. *Front Biosci.* 2007 Jan 1;12:2425–37.
 72. Lopes van Balen VA, van Gansewinkel TAG, de Haas S, Spaan JJ, Ghossein-Doha C, van Kuijk SMJ, et al. Maternal kidney function during pregnancy: systematic review and meta-analysis. *Ultrasound Obstet Gynecol.* 2019 Sep;54(3):297–307.
 73. Lam C, Lim K-H, Kang D-H, Karumanchi SA. Uric acid and preeclampsia. *Semin Nephrol.* 2005 Jan;25(1):56–60.
 74. Bainbridge SA, Roberts JM. Uric acid as a pathogenic factor in preeclampsia. *Placenta.* 2008 Mar;29 Suppl A:S67–72.
 75. Martin AC, Brown MA. Could uric acid have a pathogenic role in pre-eclampsia? *Nat Rev Nephrol.* 2010 Dec;6(12):744–8.

76. 1000 Genomes Project Consortium, Abecasis GR, Auton A, Brooks LD, DePristo MA, Durbin RM, et al. An integrated map of genetic variation from 1,092 human genomes. *Nature*. 2012 Nov 1;491(7422):56–65.
77. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O'Donnell CJ, de Bakker PIW. SNAP: a web-based tool for identification and annotation of proxy SNPs using HapMap. *Bioinformatics*. 2008 Dec 15;24(24):2938–9.
78. Li Y, Qi Q, Workalemahu T, Hu FB, Qi L. Birth weight, genetic susceptibility, and adulthood risk of type 2 diabetes. *Diabetes Care*. 2012 Dec;35(12):2479–84.
79. Cornelis MC, Qi L, Zhang C, Kraft P, Manson J, Cai T, et al. Joint effects of common genetic variants on the risk for type 2 diabetes in U.S. men and women of European ancestry. *Ann Intern Med*. 2009 Apr 21;150(8):541–50.
80. Qi Q, Forman JP, Jensen MK, Flint A, Curhan GC, Rimm EB, et al. Genetic predisposition to high blood pressure associates with cardiovascular complications among patients with type 2 diabetes: two independent studies. *Diabetes*. 2012 Nov;61(11):3026–32.
81. Qi Q, Liang L, Doria A, Hu FB, Qi L. Genetic predisposition to dyslipidemia and type 2 diabetes risk in two prospective cohorts. *Diabetes*. 2012 Mar;61(3):745–52.
82. Salfati E, Morrison AC, Boerwinkle E, Chakravarti A. Direct Estimates of the Genomic Contributions to Blood Pressure Heritability within a Population-Based Cohort (ARIC). *PLoS One*. 2015 Jul 10;10(7):e0133031.
83. Smith CJ, Saftlas AF, Spracklen CN, Triche EW, Bjorndal A, Keating B, et al. Genetic Risk Score for Essential Hypertension and Risk of Preeclampsia. *Am J Hypertens*. 2016 Jan;29(1):17–24.
84. Spracklen CN, Saftlas AF, Triche EW, Bjorndal A, Keating B, Saxena R, et al. Genetic Predisposition to Dyslipidemia and Risk of Preeclampsia. *Am J Hypertens*. 2015 Jul;28(7):915–23.
85. Spracklen CN, Smith CJ, Saftlas AF, Triche EW, Bjorndal A, Keating BJ, et al. Genetic predisposition to elevated levels of C-reactive protein is associated with a decreased risk for preeclampsia. *Hypertens Pregnancy*. 2016 Sep 22;1–10.
86. International Consortium for Blood Pressure Genome-Wide Association Studies, Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, et al. Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. *Nature*. 2011 Oct 6;478(7367):103–9.
87. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder. *Am J Obstet Gynecol*. 1989 Nov;161(5):1200–4.
88. Franceschini N, Fox E, Zhang Z, Edwards TL, Nalls MA, Sung YJ, et al. Genome-wide association analysis of blood-pressure traits in African-ancestry individuals reveals common

- associated genes in African and non-African populations. *Am J Hum Genet.* 2013 Sep 5;93(3):545–54.
89. CARDIoGRAMplusC4D Consortium, Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, et al. Large-scale association analysis identifies new risk loci for coronary artery disease. *Nat Genet.* 2013 Jan;45(1):25–33.
90. Wetzka B, Winkler K, Kinner M, Friedrich I, März W, Zahradnik HP. Altered lipid metabolism in preeclampsia and HELLP syndrome: links to enhanced platelet reactivity and fetal growth. *Semin Thromb Hemost.* 1999;25(5):455–62.
91. Perucci LO, Corrêa MD, Dusse LM, Gomes KB, Sousa LP. Resolution of inflammation pathways in preeclampsia-a narrative review. *Immunol Res.* 2017 Aug;65(4):774–89.
92. Cornelius DC. Preeclampsia: From Inflammation to Immunoregulation. *Clin Med Insights Blood Disord.* 2018 Jan 10;11:1179545X17752325.
93. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. *N Engl J Med.* 2000 Apr 27;342(17):1266–71.
94. Yang Q, Yin R-X, Cao X-L, Wu D-F, Chen W-X, Zhou Y-J. Association of two polymorphisms in the FADS1/FADS2 gene cluster and the risk of coronary artery disease and ischemic stroke. *Int J Clin Exp Pathol.* 2015 Jun 1;8(6):7318–31.
95. van de Woestijne AP, van der Graaf Y, de Bakker PIW, Asselbergs FW, de Borst GJ, Algra A, et al. LDL-c-linked SNPs are associated with LDL-c and myocardial infarction despite lipid-lowering therapy in patients with established vascular disease. *Eur J Clin Invest.* 2014 Feb;44(2):184–91.
96. Wauters E, Carruthers KF, Buysschaert I, Dunbar DR, Peuteman G, Belmans A, et al. Influence of 23 coronary artery disease variants on recurrent myocardial infarction or cardiac death: the GRACE Genetics Study. *Eur Heart J.* 2013 Apr;34(13):993–1001.
97. Quenby S, Farquharson RG, Dawood F, Hughes AM, Topping J. Recurrent miscarriage and long-term thrombosis risk: a case-control study. *Hum Reprod.* 2005 Jun;20(6):1729–32.
98. Martinez-Zamora MA, Peralta S, Creus M, Tassies D, Reverter JC, Espinosa G, et al. Risk of thromboembolic events after recurrent spontaneous abortion in antiphospholipid syndrome: a case-control study. *Ann Rheum Dis.* 2012 Jan;71(1):61–6.
99. Than NG, Romero R, Tarca AL, Kekesi KA, Xu Y, Xu Z, et al. Integrated Systems Biology Approach Identifies Novel Maternal and Placental Pathways of Preeclampsia. *Front Immunol.* 2018 Aug 8;9:1661.
100. Leavey K, Benton SJ, Grynspan D, Kingdom JC, Bainbridge SA, Cox BJ. Unsupervised Placental Gene Expression Profiling Identifies Clinically Relevant Subclasses of Human Preeclampsia. *Hypertension.* 2016 Jul;68(1):137–47.

101. Benton SJ, Leavey K, Gynspan D, Cox BJ, Bainbridge SA. The clinical heterogeneity of preeclampsia is related to both placental gene expression and placental histopathology. *Am J Obstet Gynecol*. 2018 Dec;219(6): 604.e1-604.e25

TABLES

Table 1. Collection site of European ancestry preeclampsia cases (n=498) and controls (n=1864).

Site/Study	Preeclampsia cases	Normotensive controls	Population controls
Boston	263	74	—
CHOP	69	345	—
Iowa	75	—	—
USC	80	—	—
Yale	11	30	—
ARIC	—	—	645
CARDIA	—	—	770
Total	498	449	1415

Abbreviations: CHOP = Children's Hospital of Philadelphia; USC = University of Southern California; ARIC = Atherosclerosis Risk in Communities; CARDIA = Coronary Artery Risk Development in Young Adults

Table 2. Disease categories and specific traits assessed using risk SNPs.

Disease category	Trait
Cardiovascular	Systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides, coronary artery disease (CAD), ischemic stroke
Inflammatory/ autoimmune	C-reactive protein (CRP), systemic lupus erythematosus (SLE)
Insulin resistance	Adiponectin, fasting blood glucose, type 2 diabetes mellitus (T2DM)
Liver	Alkaline phosphatase (ALP), gamma-glutamyl transferase (GTT)
Obesity	Body mass index (BMI), birthweight
Renal	Estimated glomerular filtration rate from serum creatinine (eGFR _{Cr}), uric acid
Thrombophilia	Fibrinogen, venous thromboembolism (VTE)

Table 3. Preeclampsia risk by quartiles of trait-specific risk SNPs.

TRAIT*	Q1 odds ratio (Ref)	Q2 odds ratio (95% CI)	Q3 odds ratio (95% CI)	Q4 odds ratio (95% CI)	Overall odds ratio [†] (95% CI)	p-value (for trend by quartile)
Cardiovascular						
SBP (19 SNPs)	1.00	0.82 (0.62-1.08)	0.88 (0.67-1.15)	0.84 (0.64-1.10)	0.96 (0.88-1.04)	0.322
DBP (16 SNPs)	1.00	1.37 (1.03-1.82)	1.42 (1.07-1.89)	1.39 (1.05-1.86)	1.11 (1.01-1.21)	0.025
Total cholesterol (20 SNPs)	1.00	1.03 (0.78-1.36)	0.97 (0.73-1.28)	1.10 (0.84-1.45)	1.02 (0.94-1.12)	0.589
LDL (12 SNPs)	1.00	0.95 (0.71-1.26)	1.20 (0.91-1.58)	1.13 (0.85-1.49)	1.06 (0.98-1.16)	0.164
HDL (28 SNPs)	1.00	1.01 (0.77-1.32)	0.70 (0.53-0.93)	0.87 (0.66-1.14)	0.93 (0.85-1.01)	0.096
Triglycerides (15 SNPs)	1.00	0.92 (0.70-1.21)	0.94 (0.71-1.24)	0.95 (0.72-1.26)	0.98 (0.90-1.07)	0.626
CAD (10 SNPs)	1.00	1.18 (0.88-1.57)	1.43 (1.08-1.90)	1.11 (0.82-1.51)	1.05 (0.96-1.15)	0.294
Ischemic stroke (5 SNPs)	1.00	0.95 (0.71-1.26)	0.81 (0.60-1.10)	0.97 (0.72-1.31)	0.97 (0.89-1.07)	0.584
Inflammatory/ autoimmune						
CRP (9 SNPs)	1.00	0.93 (0.70-1.23)	1.10 (0.84-1.44)	0.97 (0.73-1.28)	1.00 (0.92-1.10)	0.949
SLE (9 SNPs)	1.00	1.12 (0.85-1.48)	1.04 (0.78-1.38)	1.09 (0.82-1.44)	1.01 (0.93-1.11)	0.775
Insulin resistance						
Adiponectin (3 SNPs)	1.00	1.06 (0.74-1.51)	0.95 (0.67-1.35)	0.95 (0.66-1.36)	0.97 (0.87-1.07)	0.521
Fasting glucose (5 SNPs)	1.00	0.75 (0.56-1.00)	0.92 (0.69-1.23)	0.86 (0.65-1.15)	0.99 (0.90-1.08)	0.782
T2DM (21 SNPs)	1.00	1.17 (0.89-1.54)	0.94 (0.71-1.24)	0.97 (0.73-1.29)	0.97 (0.89-1.06)	0.470
Liver						
ALP (5 SNPs)	1.00	0.85 (0.65-1.11)	0.63 (0.47-0.84)	0.74 (0.56-0.97)	0.89 (0.82-0.97)	0.008
GTT (6 SNPs)	1.00	1.29 (0.97-1.72)	1.31 (0.99-1.74)	1.19 (0.90-1.57)	1.05 (0.97-1.15)	0.250
Obesity						
BMI (15 SNPs)	1.00	0.96 (0.72-1.27)	1.14 (0.86-1.51)	1.28 (0.97-1.69)	1.10 (1.00-1.20)	0.042

Birthweight (6 SNPs)	1.00	1.07 (0.80-1.42)	1.07 (0.80-1.44)	1.17 (0.87-1.57)	1.04 (0.95-1.13)	0.457
Renal						
eGFRcr (9 SNPs)	1.00	0.75 (0.57-0.99)	0.86 (0.66-1.13)	0.83 (0.63-1.09)	0.96 (0.88-1.05)	0.391
Uric acid (11 SNPs)	1.00	1.24 (0.94-1.65)	1.17 (0.88-1.55)	1.16 (0.88-1.54)	1.04 (0.95-1.14)	0.379
Thrombophilia						
Fibrinogen (5 SNPs)	1.00	0.91 (0.68-1.21)	0.94 (0.72-1.24)	1.06 (0.81-1.40)	1.03 (0.94-1.12)	0.565
VTE (5 SNPs)	1.00	0.99 (0.75-1.31)	0.66 (0.49-0.89)	0.89 (0.66-1.18)	0.93 (0.85-1.02)	0.101

*Specific SNPs assessed for each trait are listed in the Online Supplement

† Odds ratio reflects the per risk allele increase in preeclampsia risk, adjusted for study site and principle components of ancestry

Table 4. Early-onset preeclampsia risk by quartiles of trait-specific risk SNPs.

TRAIT*	Q1 odds ratio (Ref)	Q2 odds ratio (95% CI)	Q3 odds ratio (95% CI)	Q4 odds ratio (95% CI)	Overall odds ratio [†] (95% CI)	p-value (for trend by quartile)
<i>Delivery < 34 weeks</i>						
DBP (16 SNPs)	1.00	1.71 (0.89-3.28)	1.91 (1.00-3.64)	2.45 (1.31-4.58)	1.30 (1.08-1.56)	0.005
BMI (15 SNPs)	1.00	0.76 (0.42-1.36)	0.87 (0.50-1.51)	1.03 (0.60-1.78)	1.04 (0.87-1.24)	0.683
ALP (5 SNPs)	1.00	1.09 (0.65-1.84)	0.66 (0.37-1.18)	0.71 (0.40-1.27)	0.86 (0.72-1.03)	0.108
<i>Delivery < 37 weeks</i>						
DBP (16 SNPs)	1.00	1.73 (1.10-2.73)	1.70 (1.08-2.68)	1.91 (1.22-2.98)	1.19 (1.05-1.36)	0.009
BMI (15 SNPs)	1.00	1.00 (0.65-1.52)	0.97 (0.64-1.48)	1.17 (0.78-1.77)	1.06 (0.93-1.21)	0.400
ALP (5 SNPs)	1.00	0.81 (0.55-1.20)	0.55 (0.36-0.85)	0.60 (0.40-0.90)	0.82 (0.72-0.94)	0.004

*Specific SNPs assessed for each trait are listed in the Online Supplement

[†] Odds ratio reflects the per risk allele increase in preeclampsia risk, adjusted for study site and principle components of ancestry